Adjuvant low-dose rituximab and plasma exchange for acquired TTP

Blood. 2019 Sep 26;134(13):1106-1109. doi: 10.1182/blood.2019000795. Epub 2019 Jul 22.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Plasma Exchange*
  • Purpura, Thrombotic Thrombocytopenic / therapy*
  • Rituximab / administration & dosage
  • Rituximab / therapeutic use*
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Rituximab

Supplementary concepts

  • Thrombotic thrombocytopenic purpura, acquired